{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:12:58Z","timestamp":1788257578857,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.7759\/cureus.115576","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:14:21Z","timestamp":1788254061000},"source":"Crossref","is-referenced-by-count":0,"title":["Life-Threatening Eosinophilic Granulomatosis With Polyangiitis During Omalizumab Therapy for Chronic Urticaria: Missed Diagnosis, Induction, or Unmasking?"],"prefix":"10.7759","author":[{"given":"Panagiotis","family":"Zymaris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina","family":"Georgopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Tzioutzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Zacharias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Margaritopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evdokia","family":"Sourla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afroditi","family":"Boutou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Pitsiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103219","article-title":"Eosinophilic granulomatosis with polyangiitis: a review","volume":"22","author":"White J","year":"2023","unstructured":"White J, Dubey S. Eosinophilic granulomatosis with polyangiitis: a review. Autoimmun Rev. 2023, 22:103219. 10.1016\/j.autrev.2022.103219","journal-title":"Autoimmun Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.627776","article-title":"Eosinophilic granulomatosis with polyangiitis: dissecting the pathophysiology","volume":"8","author":"Fagni F","year":"2021","unstructured":"Fagni F, Bello F, Emmi G. Eosinophilic granulomatosis with polyangiitis: dissecting the pathophysiology. Front Med (Lausanne). 2021, 8:627776. 10.3389\/fmed.2021.627776","journal-title":"Front Med (Lausanne)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00958-w","article-title":"Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Emmi G","year":"2023","unstructured":"Emmi G, Bettiol A, Gelain E, et al.. Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2023, 19:378-93. 10.1038\/s41584-023-00958-w","journal-title":"Nat Rev Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2019.4476","article-title":"Treatment effect of omalizumab on severe pediatric atopic dermatitis: the adapt randomized clinical trial","volume":"174","author":"Chan S","year":"2020","unstructured":"Chan S, Cornelius V, Cro S, Harper JI, Lack G. Treatment effect of omalizumab on severe pediatric atopic dermatitis: the adapt randomized clinical trial. JAMA Pediatr. 2020, 174:29-37. 10.1001\/jamapediatrics.2019.4476","journal-title":"JAMA Pediatr"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer M","year":"2013","unstructured":"Maurer M, Ros\u00e9n K, Hsieh HJ, et al.. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013, 368:924-35. 10.1056\/NEJMoa1215372","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania NA","year":"2011","unstructured":"Hanania NA, Alpan O, Hamilos DL, et al.. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011, 154:573-82. 10.7326\/0003-4819-154-9-201105030-00002","journal-title":"Ann Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/art.41982","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis","volume":"74","author":"Grayson PC","year":"2022","unstructured":"Grayson PC, Ponte C, Suppiah R, et al.. 2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Arthritis Rheumatol. 2022, 74:386-92. 10.1002\/art.41982","journal-title":"Arthritis Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-240078","article-title":"Omalizumab-associated eosinophilic granulomatosis with polyangiitis: cause or coincidence?","volume":"14","author":"Carson LN","year":"2021","unstructured":"Carson LN, Pradhan A, Subramanian D. Omalizumab-associated eosinophilic granulomatosis with polyangiitis: cause or coincidence?. BMJ Case Rep. 2021, 14:e240078. 10.1136\/bcr-2020-240078","journal-title":"BMJ Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S259746","article-title":"Transient eosinophilic granulomatosis with polyangiitis-like vasculitis during omalizumab therapy: a case report","volume":"12","author":"Elhadari S","year":"2020","unstructured":"Elhadari S, Hamad M. Transient eosinophilic granulomatosis with polyangiitis-like vasculitis during omalizumab therapy: a case report. Open Access Rheumatol. 2020, 12:127-31. 10.2147\/OARRR.S259746","journal-title":"Open Access Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/art.39663","article-title":"Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients","volume":"68","author":"Jachiet M","year":"2016","unstructured":"Jachiet M, Samson M, Cottin V, et al.. Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients. Arthritis Rheumatol. 2016, 68:2274-82. 10.1002\/art.39663","journal-title":"Arthritis Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3109\/02770903.2015.1081700","article-title":"Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study","volume":"53","author":"Detoraki A","year":"2016","unstructured":"Detoraki A, Di Capua L, Varricchi G, Genovese A, Marone G, Spadaro G. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study. J Asthma. 2016, 53:201-6. 10.3109\/02770903.2015.1081700","journal-title":"J Asthma"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich B","year":"2024","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH, et al.. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024, 83:30-47. 10.1136\/ard-2022-223764","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh M","year":"2020","unstructured":"Walsh M, Merkel PA, Peh CA, et al.. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020, 382:622-31. 10.1056\/NEJMoa1803537","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.009","article-title":"Executive summary of the KDIGO 2024 clinical practice guideline for the management of ANCA-associated vasculitis","volume":"105","author":"Floege J","year":"2024","unstructured":"Floege J, Jayne DR, Sanders JF, et al.. Executive summary of the KDIGO 2024 clinical practice guideline for the management of ANCA-associated vasculitis. Kidney Int. 2024, 105:447-9. 10.1016\/j.kint.2023.10.009","journal-title":"Kidney Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/528235-life-threatening-eosinophilic-granulomatosis-with-polyangiitis-during-omalizumab-therapy-for-chronic-urticaria-missed-diagnosis-induction-or-unmasking","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:14:21Z","timestamp":1788254061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/528235-life-threatening-eosinophilic-granulomatosis-with-polyangiitis-during-omalizumab-therapy-for-chronic-urticaria-missed-diagnosis-induction-or-unmasking"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.115576","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}